Benjamin Shaker - Jan 17, 2023 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Markets Officer
Signature
/s/ Timothy Bensley, as Attorney-in-Fact
Stock symbol
AGL
Transactions as of
Jan 17, 2023
Transactions value $
-$782,779
Form type
4
Date filed
1/19/2023, 03:28 PM
Previous filing
Dec 16, 2022
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Options Exercise $77.2K +25.7K +100.38% $3.00* 51.3K Jan 17, 2023 Direct F1
transaction AGL Common Stock Sale -$512K -25.7K -50.09% $19.91 25.6K Jan 17, 2023 Direct F1, F2, F3
transaction AGL Common Stock Options Exercise $62.2K +20.7K +80.87% $3.00* 46.3K Jan 18, 2023 Direct F1
transaction AGL Common Stock Sale -$410K -20.7K -44.71% $19.78 25.6K Jan 18, 2023 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Right to buy) Options Exercise $0 -25.7K -33.47% $0.00 51.1K Jan 17, 2023 Common Stock 25.7K $3.00 Direct F5
transaction AGL Options (Right to buy) Options Exercise $0 -20.7K -40.53% $0.00 30.4K Jan 18, 2023 Common Stock 20.7K $3.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes restricted stock units.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $19.59 to $20.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $19.65 to $20.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 These options were granted on December 30, 2016 and vested on September 14, 2021.